Arnett Cancer Care

Lafayette, Indiana 47904

0 studies enrolling now · 20 studies all time

What they study most

Bladder Cancer, Breast Cancer, Chronic Lymphocytic Leukemia, Colorectal Cancer, Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Non-Hodgkin, Metastatic Breast Cancer, Multiple Myeloma, Myelodysplastic Syndromes, Ovarian Cancer

Studies at this site

• Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy — Completed
• Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes — Stopped early
• A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer — Stopped early
• Sutent + Taxol for Advanced Esophageal Cancer — Completed
• Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma — Stopped early
• A Biological Sample Collection Protocol of Women With and Without Breast Cancer — Completed
• Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer — Completed
• Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer — Completed
• Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer — Stopped early
• Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer — Completed
• Lonafarnib in Metastatic Breast Cancer — Stopped early
• Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer — Completed
• A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer — Stopped early
• PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer — Stopped early
• Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer — Completed
• Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck — Stopped early
• Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma — Stopped early
• Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer — Stopped early
• A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer — Completed
• Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. — Status unconfirmed